

CYTORI THERAPEUTICS, INC.
 Form 3
 November 17, 2006

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â REUTER BRUCE		(Month/Day/Year)	CYTORI THERAPEUTICS, INC. [CYTX]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		11/09/2006		
C/O CYTORI THERAPEUTICS, INC.,Â 3020 CALLAN ROAD			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below)	(specify below)
			Sen. VP Intern Sales, Marketin	
SAN DIEGO,Â CAÂ 92121				6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)		<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,193	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title			

Edgar Filing: CYTORI THERAPEUTICS, INC. - Form 3

		Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	100,000	\$ 7.34	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	35,000	\$ 2.51	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	30,000	\$ 3.09	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	29,895	\$ 4.4	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	13,020	\$ 4.16	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	12,396	\$ 3.12	D	Â
Employee Stock Option (Right to Buy)	11/09/2006 ⁽¹⁾	12/31/2007	Common Stock	4,375	\$ 7.04	D	Â
Employee Stock Option (Right to Buy)	12/09/2006 ⁽²⁾	11/09/2016	Common Stock	70,000	\$ 4.68	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
REUTER BRUCE C/O CYTORI THERAPEUTICS, INC. 3020 CALLAN ROAD SAN DIEGO, CA 92121	Â	Â	Â Sen. VP Intern Sales, Marketin	Â

Signatures

Bruce Reuter 11/17/2006

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Employee Stock Options are fully vested.
- (2) The Employee Stock Options vest 1/48th each month from the grant date.

Â

Remarks:

In connection with the elimination of Mr. Reuter's position of Senior Vice President of Business Development

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.